Table 3 Base case results of cost-effectiveness analysis (both direct and indirect costs were considered in the analysis)
Direct comparison | Total cost | QALYs | Incremental cost | Incremental QALYs | ICER |
|---|---|---|---|---|---|
| Â | Â | Â | Agomelatine vs. comparator | Agomelatine vs. comparator | Â |
Agomelatine | €5,434 | 1.461 | - | - | - |
Venlafaxine | €5,420 | 1.436 | €14 | 0.026 | €547/QALY |
Sertraline | €5,650 | 1.427 | - €215 | 0.034 | Agom. dominant |
Escitalopram | €5,462 | 1.447 | - €28 | 0.015 | Agom. dominant |
Fluoxetine | €5,563 | 1.431 | - €129 | 0.030 | Agom. dominant |
Generic Venlafaxine | €5,397 | 1.436 | €37 | 0.026 | €1,446/QALY |
Generic Sertraline | €5,600 | 1.427 | -€166 | 0.034 | Agom. dominant |
Generic Escitalopram | €5,386 | 1.447 | €48 | 0.015 | €3,303/QALY |
Generic Fluoxetine | €5,508 | 1.431 | -€74 | 0.030 | Agom. dominant |